Drug recall: Proparacaine eye solution due to manufacturing deviations
Akorn, Inc. is recalling Proparacaine Hydrochloride Ophthalmic Solution due to manufacturing process deviations. The voluntary recall affects 23,026 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary recall for manufacturing process deviations with no reported illnesses or injuries. Per the severity rubric, voluntary precautionary recalls are classified as Moderate (score 2).
Plain-English summary
Akorn, Inc. is recalling Proparacaine Hydrochloride Ophthalmic Solution, USP 0.5%, 15 mL bottles, due to Current Good Manufacturing Practice (CGMP) deviations in the manufacturing process. The affected lot numbers are 0L53A (expiring 10/31/2022) and 1J49A (expiring 8/31/2023). A total of 23,026 bottles have been distributed nationwide in the United States.
This is a voluntary recall initiated by Akorn, Inc. on October 13, 2022, and classified as Class II by the FDA on January 13, 2023. No illnesses or injuries have been reported in connection with this recall.
Consumers and healthcare providers who have this product should discontinue use. For questions or to report adverse events, contact Akorn, Inc. or the FDA.
The recalled product
- Product
- Proparacaine Hydrochloride Ophthalmic Solution, USP 0.5%, 15 mL per bottle, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. Distributed By: MWI Boise, ID 83705, NDC: 13985-611-15
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic / Eye drops
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 0L53A
- EXP 10/31/2022
- 1J49A
- EXP 8/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27